Filing Flows › Jaguar Health (JAGX) › Q3 2025
Jaguar Health (JAGX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Jaguar Health (JAGX) reported revenue of $3.1M for the third quarter 2025 (Q3 2025), -0.8% from a year earlier and +3% from the quarter before. Operating margin was -234.8%, net loss $9.6M (312.9% of revenue).
Jaguar Health, Q3 2025: revenue $3.1M (-0.8% year over year), operating margin -234.8%, net loss $9.6M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.1M | +3% | -0.8% |
| Operating profit | −$7.2M | — | — |
| Net earnings | −$9.6M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $3.1M in Q3 2025, down 1% year over year and up 3% from the previous quarter. Mytesi was the largest line at 97% of revenue. Canalevia lost $17K year over year (down 35%), 68% of the total change.
Operating costs exceeded revenue by $7.2M, an operating margin of -234.8%. Total costs fell 0% while revenue fell 1%. The quarter ended with a net loss of $9.6M, narrower than the previous quarter's $10.6M loss. Minority interests bore $146K of it: to shareholders the quarter was a loss of $9.5M.
Operating cash flow was −$4.7M. Non-cash charges added back $479K of depreciation and amortization and $135K of share-based compensation. Working capital and other items added $4.3M.
Questions
What was Jaguar Health's revenue in the third quarter 2025?
Jaguar Health (JAGX) reported revenue of $3.1M for the third quarter 2025 (Q3 2025), -0.8% from a year earlier and +3% from the quarter before.
Was Jaguar Health profitable in the third quarter 2025?
Operating loss was $7.2M (-234.8% of revenue) and net loss $9.6M.
Source: Jaguar Health 10-Q on SEC EDGAR.